Drugs / Icrucumab
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00782002 | Jul 2006 → Mar 2009 | cancer | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 23 trials · 2 missed | ||||||
| Phase 2 | NCT01282463 | Apr 2011 → Feb 2015 | carcinoma of urethra, renal pelvis carcinoma, ureter carcinoma, urothelial carcinoma | Eli Lilly and Company | Completed | Mixed |
| Phase 2 | NCT01234402 | Mar 2011 → Oct 2013 | breast cancer | Eli Lilly and Company | Completed | Missed primary |
| Phase 2 | NCT01111604 | Aug 2010 → Dec 2013 | colon carcinoma, rectal carcinoma | Eli Lilly and Company | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2015-09-28 | Eli Lilly and Company | Results Lilly's CYRAMZA® (ramucirumab) Significantly Improves Progression-Free Survival in Phase II Bladder Cancer Trial lilly.com ↗
Final results of the Phase II trial were presented at the European Cancer Congress (ECC2015) in Vienna, Austria (Abstract #2508) on September 27. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2015-09-28 | Eli Lilly and Company | Lilly's CYRAMZA® (ramucirumab) Significantly Improves Progression-Free Survival in Phase II Bladder Cancer Trial lilly.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | icrucumab | “Icrucumab (ICR) and ramucirumab (RAM) bind vascular endothelial growth factor (VEGF) receptors 1 and 2 (VEGFR-1 and -2), respectively.” PMID 28220020 ↗ Feb 20173“IMC-18F1 (icrucumab), a human monoclonal antibody against vascular endothelial growth factor receptor-1 (VEGFR-1)” PMID 23903897 ↗ Aug 2013 |
| Known as | ICR | “Icrucumab (ICR) and ramucirumab (RAM) bind vascular endothelial growth factor (VEGF) receptors 1 and 2 (VEGFR-1 and -2), respectively.” PMID 28220020 ↗ Feb 2017 |
| Known as | IMC-18F1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00782002 ↗ |
| Action | Inhibit | “potently inhibits ligand-dependent phosphorylation of VEGFR-1 and downstream signaling” PMID 23903897 ↗ Aug 20131“Vascular endothelial growth factor receptor 1 antagonist” CHEMBL1743030 ↗ |
| Modality | Monoclonal antibody | “a human monoclonal antibody against vascular endothelial growth factor receptor-1 (VEGFR-1)” PMID 23903897 ↗ Aug 2013 |
| Route | Intravenous | “12 mg/kg IV, days 1 and 8” PMID 28220020 ↗ Feb 2017 |
| Target | FLT1 | “Vascular endothelial growth factor receptor 1 antagonist” CHEMBL1743030 ↗ |